Pulmonx Corporation
  1. Companies
  2. Products
  3. Inpro - 1700 High Impact Door Frame ...

ChartisPulmonary Assessment System

SHARE

The Chartis® Pulmonary Assessment System is a proprietary balloon catheter and console with flow and pressure sensors used to assess the presence of collateral ventilation (CV). It is a physiological measure of collateral ventilation.

Most popular related searches

When the balloon is inflated, the target lobe is blocked, and the air can only escape through the catheter’s central lumen. Airflow and pressure are displayed on the Chartis Console allowing for a simulation of an “occluded lobe” and the measurement of any collateral ventilation in the targeted lobe.

Used prior to placement of valves, Chartis helps physicians predict likely responders to the Zephyr Valve treatment and is a critical addition to analysis of fissure completeness. Without Chartis, physicians may treat a lobe that has collateral ventilation, or unnecessarily rule out a patient who could have benefitted.

The Chartis System has been used in multiple randomized clinical trials1-5 to predict likely responders to the Zephyr Valve treatment. It provides precise flow and pressure readings for specific lobes in the lung to assess the absence of collateral ventilation, which is a predictor of response to treatment.

Patient Selection Benefit of Chartis

A detailed survey of 294 severe emphysema patients evaluated how they balance potential risks and benefits. The study concluded that patients with severe emphysema value access to an interventional treatment that offers benefits above and beyond their current medical management, despite the risks associated with these treatments.